Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash from Operations (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Cash from Operations for 10 consecutive years, with 99829000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 25.86% to 99829000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 466000000.0, a 12.56% decrease, with the full-year FY2025 number at 466000000.0, down 12.56% from a year prior.
  • Cash from Operations was 99829000.0 for Q4 2025 at Ultragenyx Pharmaceutical, down from 91423000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 54344000.0 in Q4 2021 to a low of 190727000.0 in Q1 2024.
  • A 5-year average of 103708000.0 and a median of 93384000.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: tumbled 174.82% in 2021, then surged 43.16% in 2024.
  • Ultragenyx Pharmaceutical's Cash from Operations stood at 54344000.0 in 2021, then tumbled by 66.24% to 90342000.0 in 2022, then increased by 6.91% to 84098000.0 in 2023, then grew by 5.69% to 79315000.0 in 2024, then dropped by 25.86% to 99829000.0 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Cash from Operations are 99829000.0 (Q4 2025), 91423000.0 (Q3 2025), and 108273000.0 (Q2 2025).